Skip to main content
Top
Published in: Supportive Care in Cancer 10/2018

01-10-2018 | Original Article

Chemosensory changes and quality of life in patients undergoing hematopoietic stem cell transplantation

Authors: Rania Abasaeed, Susan E. Coldwell, Michele E. Lloid, Sohaib H. Soliman, Paula C. Macris, Mark M. Schubert

Published in: Supportive Care in Cancer | Issue 10/2018

Login to get access

Abstract

Purpose

To assess magnitude and characteristics of changes in chemosensory function and quality of life (QOL) for patients receiving hematopoietic stem cell transplantation (HSCT).

Methods

Patients (aged 18 years and above) scheduled to undergo HSCT at the Seattle Cancer Care Alliance were tested for chemosensory function at three time points: pre-transplant (baseline), 30 ± 5 days (day 30), and 80 ± 5 days (day 80) post-HSCT. Gustatory function was assessed following procedures developed at the Monell-Jefferson Taste and Smell Clinic. Olfactory testing was conducted using the National Institute of Health Toolbox Odor Identification test. QOL was also assessed.

Results

Twenty-nine patients were enrolled in the study between August 2014 and March 2015. Twenty-three patients were included in the analysis, with 16 tested at all three time points (baseline, day 30, and day 80). The primary finding is decreased taste sensitivity for 0.32 M NaCl, 0.0056 M citric acid, and 0.018 M citric acid on day 30 following HSCT. Increased taste sensitivity for 0.32 M sucrose at day 30 was also observed. Taste sensitivity largely recovered by day 80. Olfactory identification scores were unchanged from baseline to day 30. QOL was reduced at day 30 but was restored to an acceptable level of functioning and symptoms by day 80. However, some areas remain impaired.

Conclusions

Alterations in taste perception were confirmed in the early post-transplant period. This was largely resolved within 2.5 months. No obvious impairments were observed in olfactory function. QOL improved by day 80, though some oral symptoms lingered.
Literature
2.
go back to reference Hamadani M, Mohty M, Kharfan-Dabaja M (2011) Reduced intensity conditioning allogeneic HCT in adults with acute myeloid leukemia. Cancer Control 18(4):237–245CrossRefPubMed Hamadani M, Mohty M, Kharfan-Dabaja M (2011) Reduced intensity conditioning allogeneic HCT in adults with acute myeloid leukemia. Cancer Control 18(4):237–245CrossRefPubMed
3.
go back to reference Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y, Worldwide Network of Blood and Marrow Transplantation (2010) Hematopoietic stem cell transplantation: a global perspective. J Am Med Assoc 303:1617–1162CrossRef Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y, Worldwide Network of Blood and Marrow Transplantation (2010) Hematopoietic stem cell transplantation: a global perspective. J Am Med Assoc 303:1617–1162CrossRef
4.
go back to reference Epstein JB, Phillips N, Parry J, Epstein MS, Nevill T, Stevenson-Moore P (2002) Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30:785–792CrossRefPubMed Epstein JB, Phillips N, Parry J, Epstein MS, Nevill T, Stevenson-Moore P (2002) Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30:785–792CrossRefPubMed
5.
go back to reference McIssac T (2008) Chemosensory dysfunction in advanced cancer patients. MS. Thesis. University of Alberta: Canada McIssac T (2008) Chemosensory dysfunction in advanced cancer patients. MS. Thesis. University of Alberta: Canada
6.
go back to reference Marinone MG, Rizzoni D, Ferremi P, Rossi G, Izzi T, Brusotti C (1991) Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients. Haematologica 76:519–522PubMed Marinone MG, Rizzoni D, Ferremi P, Rossi G, Izzi T, Brusotti C (1991) Late taste disorders in bone marrow transplantation: clinical evaluation with taste solutions in autologous and allogeneic bone marrow recipients. Haematologica 76:519–522PubMed
7.
go back to reference Hull KM, Kerridge I, Schifter M (2012) Long-term oral complications of allogeneic haematopoietic SCT. Bone Marrow Transplant 47(2):265–270CrossRefPubMed Hull KM, Kerridge I, Schifter M (2012) Long-term oral complications of allogeneic haematopoietic SCT. Bone Marrow Transplant 47(2):265–270CrossRefPubMed
8.
go back to reference Lenssen P, Sherry MA, Cheney CL, Nims JW, Sullivan KM, Stern JM, Moe G, Aker SN (1990) Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation. J Am Diet Assoc 90:835–842PubMed Lenssen P, Sherry MA, Cheney CL, Nims JW, Sullivan KM, Stern JM, Moe G, Aker SN (1990) Prevalence of nutrition-related problems among long-term survivors of allogeneic marrow transplantation. J Am Diet Assoc 90:835–842PubMed
9.
go back to reference Iestra JA, Fibbe WE, Zwinderman AH, Van Staveren WA, Kromhout D (2002) Body weight recovery, eating difficulties and compliance with dietary advice in the first year after stem cell transplantation: a prospective study. Bone Marrow Transplant 29:417–424CrossRefPubMed Iestra JA, Fibbe WE, Zwinderman AH, Van Staveren WA, Kromhout D (2002) Body weight recovery, eating difficulties and compliance with dietary advice in the first year after stem cell transplantation: a prospective study. Bone Marrow Transplant 29:417–424CrossRefPubMed
10.
go back to reference Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:3665–3376CrossRef Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:3665–3376CrossRef
11.
go back to reference Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50:441–450CrossRefPubMed Groenvold M, Klee MC, Sprangers MA, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50:441–450CrossRefPubMed
12.
go back to reference Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S (1995) Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 13:1249–1254CrossRefPubMed Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S (1995) Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 13:1249–1254CrossRefPubMed
13.
go back to reference Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, Biörklund A, de Leeuw JR, Fayers PM, Jannert M, Westin T, Kaasa S (1999) Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 14:1008–1019CrossRef Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, Biörklund A, de Leeuw JR, Fayers PM, Jannert M, Westin T, Kaasa S (1999) Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 14:1008–1019CrossRef
15.
go back to reference Pribitkin E, Rosenthal MD, Cowart BJ (2003) Prevalence and causes of severe taste loss in a chemosensory clinic population. Ann Otol Rhino Laryngol 112(11):971–978CrossRef Pribitkin E, Rosenthal MD, Cowart BJ (2003) Prevalence and causes of severe taste loss in a chemosensory clinic population. Ann Otol Rhino Laryngol 112(11):971–978CrossRef
17.
go back to reference Andersson I, Ahlberg K, Stockelberg D, Brune M, Persson L-O (2009) Health-related quality of life in patients undergoing allogenic cell transplantation after reduced intensity conditioning versus myeloablative conditioning. Cancer Nurs 32(4):325–334CrossRefPubMed Andersson I, Ahlberg K, Stockelberg D, Brune M, Persson L-O (2009) Health-related quality of life in patients undergoing allogenic cell transplantation after reduced intensity conditioning versus myeloablative conditioning. Cancer Nurs 32(4):325–334CrossRefPubMed
18.
go back to reference Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting LS et al (2010) A systemic review of dysgeusia induced by cancer therapies. Support Care Cancer 18(8):1081–1087CrossRefPubMed Hovan AJ, Williams PM, Stevenson-Moore P, Wahlin YB, Ohrn KE, Elting LS et al (2010) A systemic review of dysgeusia induced by cancer therapies. Support Care Cancer 18(8):1081–1087CrossRefPubMed
19.
go back to reference Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllof G, Ringden O (1992) Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med 21:33–37CrossRefPubMed Mattsson T, Arvidson K, Heimdahl A, Ljungman P, Dahllof G, Ringden O (1992) Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med 21:33–37CrossRefPubMed
20.
go back to reference Boer CC, Correa ME, Miranda EC, de Souza CA (2010) Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 45(4):705–711CrossRefPubMed Boer CC, Correa ME, Miranda EC, de Souza CA (2010) Taste disorders and oral evaluation in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 45(4):705–711CrossRefPubMed
22.
go back to reference Zervakis J, Graham BG, Schiffman SS (2000) Taste effects of lingual application of cardiovascular medications. Physiol Behav 68(3):405–413CrossRefPubMed Zervakis J, Graham BG, Schiffman SS (2000) Taste effects of lingual application of cardiovascular medications. Physiol Behav 68(3):405–413CrossRefPubMed
23.
go back to reference Fernando I, Patel T, Billingham L et al (1995) The effect of head and neck irradiation on taste dysfunction: a prospective study. Clin Oncol 7:173–178CrossRef Fernando I, Patel T, Billingham L et al (1995) The effect of head and neck irradiation on taste dysfunction: a prospective study. Clin Oncol 7:173–178CrossRef
25.
go back to reference Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP (2003) Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 14:213–225CrossRefPubMed Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP (2003) Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 14:213–225CrossRefPubMed
26.
go back to reference Bernstein IL (1985) Learned food aversions in the progression of cancer and its treatment. Ann N Y Acad Sci 443:365–380CrossRefPubMed Bernstein IL (1985) Learned food aversions in the progression of cancer and its treatment. Ann N Y Acad Sci 443:365–380CrossRefPubMed
Metadata
Title
Chemosensory changes and quality of life in patients undergoing hematopoietic stem cell transplantation
Authors
Rania Abasaeed
Susan E. Coldwell
Michele E. Lloid
Sohaib H. Soliman
Paula C. Macris
Mark M. Schubert
Publication date
01-10-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4200-7

Other articles of this Issue 10/2018

Supportive Care in Cancer 10/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine